Shreveport, La. – September 29, 2026 -- Pathology Ventures, LLC (PVL), a physician-founded network representing more than 500 pathologists, has appointed Dominic Stockey as executive vice president to lead partnerships with pharmaceutical, diagnostic and research sponsors.
Former investment banker to run sponsor and enterprise development
Stockey joins PVL after seven years in investment banking, where he served as Vice President and worked on more than 15 closed transactions across diagnostics, life sciences and healthcare, including mergers and acquisitions and capital formation deals. At PVL, he will oversee business operations, sponsor and partner relationships, commercialization, contracting and program execution.
PVL positions biomarker standards as commercial platform for industry sponsors
PVL allows pathology practices to collaborate on biomarker programs and industry projects while retaining ownership of their groups. The company was founded in 2025 by Samuel K. Caughron, MD, Eric F. Glassy, MD, and Vivek K. Khare, MD.
"Pharmaceutical and diagnostic companies want to work with pathology practices, but they need a partner that can bring those practices together around consistent standards and deliver programs at scale," said Stockey.
Executives to meet sponsors at CAP26 in Las Vegas, Oct. 3-6
Stockey and PVL leadership will attend CAP26, the College of American Pathologists annual meeting, at the Wynn Las Vegas from Oct. 3-6, where they plan to meet with sponsor and industry partners.